Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROUD: rhPro-UK for Acute Ischemic Stroke 4.5-6 Hours Post-Onset
NCT03578822Phase 3Completed
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Feb 2020
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human prourokinase in ischemic stroke (2 arms), sponsored by Tasly Biopharmaceuticals Co., Ltd. Primary endpoint: Functional handicap (modified Rankin Scale) at 90 days. Started Aug 2018; status: completed.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03578822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578822.